Cencora vs ElevenLabs
Side-by-side comparison of AI visibility scores, market position, and capabilities
Conshohocken PA pharmaceutical distribution (NYSE: COR, formerly AmerisourceBergen) at $316B+ revenue; Retina Consultants of America acquisition $4.4B (Jan 2025) expanding into specialty physician care competing with McKesson.
About
Cencora, Inc. (formerly AmerisourceBergen, rebranded August 2023) is a Conshohocken, Pennsylvania-based pharmaceutical distribution and healthcare services company — publicly traded on the New York Stock Exchange (NYSE: COR) as an S&P 500 Health Care component, ranked #10 on the 2024 Fortune 500 and #24 on the Global Fortune 500 — distributing brand-name, generic, and specialty pharmaceuticals, over-the-counter products, and home healthcare supplies to 110,000+ points of care across 11 countries through 46,000+ employees and $316+ billion in annual revenue. Cencora operates as one of the "Big Three" pharmaceutical wholesalers in the United States alongside McKesson and Cardinal Health, collectively supplying approximately 90%+ of the US pharmaceutical supply chain. The company distributes from 26 US pharmaceutical distribution centers and 1,300+ locations across 50+ countries. In January 2025, Cencora completed the acquisition of approximately 85% interest in Retina Consultants of America (RCA) — a leading management services organization for retina specialists — for $4.4 billion, advancing its strategy to expand from pharmaceutical distribution into specialty physician-administered treatments and the high-growth specialty pharmaceutical services market. Founded through the 2001 merger of AmeriSource Health Corporation and Bergen Brunswig Corporation, with predecessor companies tracing to the 1970s, Cencora adopted its current name (meaning "center, core, heart" in multiple languages) in 2023 to signal the brand's evolution beyond commodity distribution.
$500M Series D at $11B valuation (Feb 2026) — largest voice AI funding round ever. $330M ARR; 1M+ developers using the API. Enterprise customers: Deutsche Telekom, Revolut, Meta, Salesforce. Voices in 32 languages; real-time cloning from 1 second of audio.
About
ElevenLabs was founded in 2022 by Piotr Dabkowski and Mati Staniszewski, two former Google and Palantir engineers who set out to break the language barrier using AI voice technology. The company specializes in AI-powered voice synthesis, cloning, and dubbing, enabling developers and enterprises to generate human-quality speech in over 30 languages. Its core technology combines deep learning models trained on massive speech datasets to produce natural-sounding voices indistinguishable from real humans.\n\nElevenLabs offers a suite of products including its flagship text-to-speech API, voice cloning tools, and an AI dubbing platform that localizes video content while preserving the speaker's original voice. Its products target a broad audience—from indie developers building audio apps to large enterprises deploying voice interfaces at scale. Key differentiators include ultra-low latency streaming synthesis, fine-grained voice customization, and a growing library of pre-built AI voices across accents and styles.\n\nElevenLabs has grown rapidly, surpassing $330M in annualized revenue and serving over 1 million developers. Enterprise clients include Deutsche Telekom, Spotify, and leading media companies. In February 2026, the company closed a $500M Series D at an $11B valuation, cementing its position as the market leader in AI voice. Its APIs power podcasts, audiobooks, video games, and customer service bots worldwide, making ElevenLabs the default infrastructure layer for AI-generated audio.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.